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BSTRACT
 
Background
 
Several epidemiologic studies have
concluded that there is no relation between total cho-
lesterol levels and the risk of stroke. In some studies
that classified strokes according to cause, there was
an association between increasing cholesterol levels
and the risk of ischemic stroke and a possible as-
sociation between low cholesterol levels and the risk
of hemorrhagic stroke. Recent reviews of trials of
3-hydroxy-3-methylglutaryl–coenzyme A reductase in-
hibitors have suggested that these agents may re-
duce the risk of stroke.
 
Methods
 
In a double-blind trial (the Long-Term Inter-
vention with Pravastatin in Ischaemic Disease study),
we compared the effects of pravastatin on mortality
due to coronary heart disease (the primary end point)
with the effects of placebo among 9014 patients with
a history of myocardial infarction or unstable angina
and a total cholesterol level of 155 to 271 mg per dec-
iliter (4.0 to 7.0 mmol per liter). Our goal in the present
study was to assess effects on stroke from any cause
and nonhemorrhagic stroke, which were secondary
end points.
 
Results
 
There were 419 strokes among 373 patients
over a follow-up period of six years. A total of 309
strokes were classified as ischemic, 31 as hemorrhag-
ic, and 79 as of unknown type. Among the patients
given placebo, the risk of stroke was 4.5 percent, as
compared with 3.7 percent among those given prava-
statin (relative reduction in risk, 19 percent; 95 percent
confidence interval, 0 to 34 percent; P=0.05). Non-
hemorrhagic stroke occurred in 4.4 percent of the pa-
tients given placebo, as compared with 3.4 percent of
those given pravastatin (reduction in risk, 23 percent;
95 percent confidence interval, 5 to 38 percent; P=
0.02). Pravastatin had no effect on hemorrhagic stroke
(incidence, 0.2 percent in the placebo group vs. 0.4
percent in the pravastatin group; P=0.28).
 
Conclusions
 
Pravastatin has a moderate effect in
reducing the risk of stroke from any cause and the
risk of nonhemorrhagic stroke in patients with previ-
ous myocardial infarction or unstable angina. (N Engl
J Med 2000;343:317-26.)
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EREBROVASCULAR disease is the sec-
ond leading cause of death worldwide
 
1,2
 
 and
the leading cause of long-term disability in
developed countries.
 
3,4
 
 There has been con-
troversy about whether there is an association be-
tween cholesterol levels and the risk of stroke; a
meta-analysis found no clear evidence of such an as-
C
 
sociation.
 
5
 
 Most of the studies made no distinction
between ischemic and hemorrhagic strokes, which
have different pathophysiologic mechanisms. A posi-
tive association between increasing cholesterol levels
and ischemic stroke due to atherothrombosis in a large
artery may be offset by a possible association be-
tween low cholesterol levels and hemorrhagic stroke.
Studies of the relation between cholesterol levels
at base line and ischemic stroke have reported a pos-
itive association.
 
2,6
 
 The Multiple Risk Factor Inter-
vention Trial found a positive, continuous relation
between cholesterol levels and the risk of ischemic
stroke. However, the risk of intracerebral hemorrhage
was greater at low levels of cholesterol than at high
levels, and this risk was associated with hypertension.
 
6
 
A meta-analysis of the incidence of stroke in Asian
populations showed a positive relation between in-
creasing cholesterol levels and the incidence of non-
hemorrhagic stroke.
 
2
 
In trials of diet, clofibrate, niacin, colestipol, cho-
lestyramine, gemfibrozil, or partial ileal-bypass sur-
gery, cholesterol was lowered by 6 to 23 percent,
but no trial identified a significant reduction in rates
of stroke. Meta-analysis also showed no effect of these
treatments on rates of stroke, as compared with pla-
cebo or no treatment (relative risk, 1.0; 95 percent
confidence interval, 0.8 to 1.6).
 
7
 
Several trials of 3-hydroxy-3-methylglutaryl–coen-
zyme A reductase inhibitors (statins) have reported
reductions of 25 to 30 percent in the rate of stroke.
 
8-11
 
However, many of these trials were limited by the small
number of strokes (reducing the precision of the es-
timates) and by failure to classify the types of stroke.
In the Long-Term Intervention with Pravastatin
in Ischaemic Disease (LIPID) study, we randomly
assigned patients with previous myocardial infarc-
tion or unstable angina to receive pravastatin or pla-
cebo. Data on the primary end point, death due to
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coronary heart disease, were published previously.
 
12
 
Here we present the findings on the overall inci-
dence of stroke and the incidence of various types of
stroke, which were secondary end points.
 
METHODS
 
Study Design and Patients
 
The design of the LIPID study has been described previously.
 
12,13
 
A total of 9014 patients, 31 to 75 years of age, were recruited in
Australia and New Zealand between June 1990 and December
1992. Patients were eligible for the study if they had had a myo-
cardial infarction or unstable angina pectoris during the previous
3 to 36 months. For patients to proceed to randomization, the
total cholesterol level had to be 155 to 271 mg per deciliter (4.0
to 7.0 mmol per liter) and the fasting triglyceride level had to be
less than 445 mg per deciliter (5.0 mmol per liter). Exclusion cri-
teria included a clinically significant medical or surgical event dur-
ing the previous three months, cardiac failure, or a left ventricular
ejection fraction known to be less than 25 percent.
After stratification according to qualifying diagnosis (myocar-
dial infarction or unstable angina pectoris) and clinical center, pa-
tients were randomly assigned in a double-blind manner to receive
either 40 mg of pravastatin (Pravachol, Bristol-Myers Squibb) or
a matching placebo once daily. The sample size was calculated on
the assumption that there would be 700 deaths from coronary
heart disease. Five interim analyses were planned to examine dif-
ferences between the study groups in overall mortality and the
rate of adverse events. The study was to be stopped, on the rec-
ommendation of the data and safety monitoring board, if the pre-
specified boundary for a difference between the groups in overall
mortality (3 SD, P<0.003) was crossed. All the patients gave writ-
ten informed consent, and the study was approved by the ethics
committee at each participating center. 
The primary end point of the LIPID study was death due to
coronary heart disease. Prespecified secondary end points includ-
ed stroke from any cause (total stroke), subtypes of nonhemor-
rhagic stroke, and hemorrhagic stroke.
 
Assessment of Stroke
 
All events reported as strokes were reviewed by a Stroke Assess-
ment Committee made up of three neurologists and two Man-
agement Committee members. The reviewers were blinded with
respect to study-group assignment. Confirmation that a stroke
had occurred and classification of the stroke required agreement
between at least two of the three neurologists or the consensus
of the entire Stroke Assessment Committee.
 
Definitions
 
Stroke was defined as an acute new disturbance of focal neuro-
logic function resulting in death or lasting longer than 24 hours
and thought to be due to intracranial hemorrhage or ischemia.
Each stroke was first classified as ischemic, hemorrhagic, or of un-
known type.
Ischemic stroke was defined as a stroke accompanied by a com-
puted tomographic (CT) or magnetic resonance imaging (MRI)
scan within three weeks after onset that either was normal or
showed an infarct in the expected area on the basis of the clinical
findings or a stroke for which there was evidence of cerebral infarc-
tion at autopsy. Each ischemic stroke was classified as one of the
following: a cerebral infarct in a large artery (with evidence on clin-
ical examination, duplex ultrasonography, MRI, or angiography of
disease in an extracranial or intracranial large artery, but with no
cardioembolic source); a cerebral infarct in a small artery (with
preservation of consciousness and higher cerebral function, a lacu-
nar syndrome, and a CT or MRI scan that was normal or showed
a small infarct in the basal ganglia, internal capsule, or brain stem);
a cerebral infarct of cardioembolic cause (with a major cardioem-
bolic source but no definite evidence of occlusive disease in a large
artery); a retinal infarct
 
14
 
; or a cerebral infarct of unknown or un-
certain origin. Each hemorrhagic stroke was classified as due to ei-
ther a subarachnoid hemorrhage or an intracerebral hemorrhage
(on the basis of evidence obtained on CT or MRI scanning or at
autopsy), excluding hemorrhagic conversion of infarction.
A stroke was considered to be of unknown type if there was no
information available from CT or MRI scanning or from autopsy
findings. In addition, each stroke was classified according to wheth-
er it occurred within seven days after enrollment and whether it
was related to coronary angiography, angioplasty, bypass surgery,
or other similar procedures.
 
Disability
 
Patients’ functional status was assessed at hospital discharge or
30 days after the event, whichever came first. Disability was clas-
 
*Except for base-line triglyceride levels (P=0.02), there were no signif-
icant differences between the groups.
†Obesity was defined as a body-mass index (the weight in kilograms di-
vided by the square of the height in meters) above 30.
‡The percentage of patients receiving medication is marginally lower
than previously reported,
 
12
 
 after correction for the use of multiple drugs in
each class of drugs.
§HDL denotes high-density lipoprotein, and LDL low-density lipopro-
tein. To convert values for cholesterol to millimoles per liter, multiply by
0.02586; to convert values for triglycerides to millimoles per liter, multiply
by 0.01129.
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V
 
ARIABLE
 
P
 
LACEBO
 
(N=4502)
P
 
RAVASTATIN
 
(N=4512)
 
Median age (yr) 62 62
Sex (%)
Male
Female
83
17
83
17
Qualifying event (%)
Myocardial infarction
Unstable angina pectoris
64
36
64
36
Median time from event to randomization (yr) 1.2 1.1
Coronary risk factors (%)
Current smoking
Former smoking
History of hypertension
Antihypertensive medication
Diabetes mellitus
Obesity†
10
63
42
38
9
18
9
65
41
36
9
18
Other vascular disease (%)
Claudication
Stroke
Transient ischemic attack
10
4
4
10
4
3
Atrial fibrillation (%) 1.3 1.4
Coronary revascularization (%)
Angioplasty only
Coronary bypass only
Both angioplasty and coronary bypass
11
27
3
11
27
3
Medications (%)‡
Aspirin
Other antiplatelet agent
Warfarin
Beta-blocker
Calcium antagonist
Angiotensin-converting–enzyme inhibitor
Nitrate
Diuretic
Insulin
Oral hypoglycemic agent
82
3
2
48
35
16
30
16
1
5
82
3
2
46
34
16
30
15
1
4
Median lipid levels§
Total cholesterol (mg/dl)
HDL cholesterol (mg/dl)
LDL cholesterol (mg/dl)
Triglycerides (mg/dl)
Total:HDL cholesterol ratio
218
36
150
138
6
218
36
150
142
6
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sified as severe (inability to live independently), moderate (sub-
stantial limitations), or minor (functional status unchanged). The
need for additional care at home was also assessed.
 
Statistical Analysis
 
All analyses were performed on an intention-to-treat basis, and
P values were two-sided. Reductions in risk and 95 percent con-
fidence intervals were estimated with use of the Cox proportion-
al-hazards model and relate to the number of patients, not the
number of strokes or other events.
 
15
 
 The times to events were an-
alyzed by the log-rank test, with stratification according to the
event that had qualified the patient for enrollment (previous my-
ocardial infarction or unstable angina pectoris).
 
16
 
 Assessment of
variation in the effects of treatment among subgroups defined ac-
cording to variables assessed before randomization was based on
tests for interaction in the Cox model. The effect of nonfatal cor-
onary events on the time to stroke was assessed with the use of
Cox regression analysis, in which the coronary event was a time-
dependent, binary covariate that switched value when a nonfatal
coronary event occurred. The effects of treatment on measure-
ments of lipids and blood pressure in the two study groups were
expressed as group means and compared with the use of t-tests.
P values for comparisons between subgroups were unadjusted for
multiple comparisons.
Base-line risk factors for stroke from any cause were identified
by backward selection in the Cox proportional-hazards model.
 
15
 
Relative risks were based on estimates of the hazard ratios, with
95 percent confidence intervals. Similar analysis was also per-
formed with nonhemorrhagic stroke as an outcome.
 
RESULTS
 
Base-Line Characteristics
 
Table 1 lists the base-line characteristics of the 9014
enrolled patients, 4512 of whom were randomly as-
signed to receive pravastatin and 4502 to receive pla-
cebo. The two groups were well matched; the only
significant difference was a slightly higher level of
plasma triglycerides in the pravastatin group. The
median age of the patients was 62 years, and 39 per-
cent were 65 years of age or older. Forty-two per-
cent had a total cholesterol level of less than 213 mg
per deciliter (5.5 mmol per liter) at base line. Eighty-
two percent of each group were taking aspirin, and
2 percent of each group were taking warfarin.
Four percent of the patients in each group had a
history of stroke. On average, these patients were
four years older than the patients without a history
of stroke and were more likely to have a history of hy-
pertension, diabetes, peripheral vascular disease, tran-
sient ischemic attack, or atrial fibrillation (P<0.001
for all comparisons).
 
Effect of Pravastatin as Compared with Placebo
 
The mean duration of treatment and follow-up
was six years. In the pravastatin group, during the
first five years, the total cholesterol level decreased
from 218 mg per deciliter (5.6 mmol per liter) to
179 mg per deciliter (4.6 mmol per liter), a reduc-
tion of 18 percent (a reduction 18 percentage points
greater than the reduction in the placebo group).
The low-density lipoprotein (LDL) cholesterol level
in the pravastatin group, initially 150 mg per deci-
liter (3.9 mmol per liter), decreased by 27 percent
(a reduction 25 percentage points greater than that
in the placebo group); the plasma triglyceride level,
initially 142 mg per deciliter (1.6 mmol per liter) de-
creased by 6 percent (a change 11 percentage points
different from that in the placebo group); and the
high-density lipoprotein (HDL) cholesterol level, ini-
tially 36 mg per deciliter, increased by 4 percent
(a change 5 percentage points different from that in
the placebo group) (P<0.001 for all comparisons).
In the pravastatin group, there was a 24 percent
relative reduction in the risk of death due to coro-
nary heart disease (6.4 percent, vs. 8.3 percent in the
placebo group; P<0.001), and a 22 percent relative
reduction in the risk of death from all causes (11
percent vs. 14.1 percent, P<0.001).
 
13
 
All 471 events reported as strokes were reviewed,
and 419 were confirmed. CT or MRI was performed
for 82 percent of the strokes. Imaging was not per-
formed in 45 patients in the placebo group and 31
patients in the pravastatin group. In the placebo
group, 231 strokes occurred in 204 of the 4502 pa-
tients (4.5 percent), and in the pravastatin group,
188 strokes occurred in 169 of the 4512 patients
(3.7 percent), a relative reduction in risk of 19 per-
cent (95 percent confidence interval, 0 to 34 per-
cent; P=0.05) (Table 2 and Fig. 1A). This risk re-
duction corresponds to the occurrence of strokes in
 
*CI denotes confidence interval. Negative numbers indicate an increase in risk.
†Percentages are of the total number of patients with stroke.
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(95% CI)*
 
no. no. (%) %
 
Patients with stroke
Patients with a single stroke
Patients with multiple strokes
204
179
25
169
153
16
373
332 (89)†
41 (11)†
19 (0 to 34)  
16 (¡4 to 32)
37 (¡19 to 66)
Total strokes 231 188 419
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Figure 1.
 
 Kaplan–Meier Estimates of the Incidence of Stroke from Any Cause (Panel A) and Nonhemorrhag-
ic Stroke (Panel B), According to Study Group.
The P values were calculated by the log-rank test.
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8 fewer patients for every 1000 patients treated with
pravastatin instead of placebo for six years. Nonhem-
orrhagic strokes occurred in 4.4 percent of the pa-
tients assigned to placebo and in 3.4 percent of those
assigned to pravastatin, a relative reduction in risk of
23 percent (95 percent confidence interval, 5 to 38
percent; P=0.02) (Fig. 1B). This risk reduction cor-
responds to the occurrence of nonhemorrhagic stroke
in 9 fewer patients for every 1000 patients treated
with pravastatin for six years.
Table 2 shows the reduction in the risk of stroke
in the two treatment groups, and Figure 2 shows the
risk of particular types of stroke. Sensitivity analysis
that excluded retinal infarctions (five in the prava-
statin group and one in the placebo group) did not
change the results. There was no significant differ-
ence between the two groups in the incidence of
hemorrhagic stroke (0.2 percent in the placebo group
and 0.4 percent in the pravastatin group, P=0.28).
At the completion of the study, the percentages of
patients using aspirin (84 percent of the placebo
group and 83 percent of the pravastatin group) or
warfarin (7 percent of the placebo group and 6 per-
cent of the pravastatin group) were similar in the two
groups. In both groups, blood pressure increased dur-
ing the study (from 133/79 at base line to 135/80
mm Hg in the placebo group and from 133/79 to
135/81 mm Hg in the pravastatin group; P=0.73
for the comparison of systolic pressure and P=0.63
for the comparison of diastolic pressure).
Table 3 shows the overall incidence of stroke in
various subgroups of the patients. Similar reductions
in risk were seen in most subgroups. There was a
greater relative reduction in the risk of stroke among
patients with low HDL cholesterol levels than among
those with high HDL cholesterol levels, but there
was no statistical evidence of heterogeneity of the ef-
fect of treatment on the risk of stroke when all of
the subgroups were considered together (P=0.75).
 
Relation between Events during the Study and Stroke
 
In both the placebo group and the pravastatin
group, more strokes occurred among the patients in
whom unstable angina or myocardial infarction de-
veloped during the study than among those in whom
these conditions did not develop (Table 4). Stroke
without a previous event occurred in 4.6 percent of
the placebo group and 3.6 percent of the pravastatin
group. The rates of stroke after any nonfatal coronary
event were 13.9 and 12.9 per 1000 person-years in the
placebo and pravastatin groups, respectively. Among
the patients who had not had a coronary event, the
rates of stroke were 6.9 and 5.5 per 1000 person-
years in the placebo and pravastatin groups, respec-
tively. The reduction in risk did not differ significantly
between the periods before and after a nonfatal cor-
onary event (P>0.48 for all comparisons). The rel-
ative reduction in risk associated with pravastatin af-
ter adjustment for all nonfatal coronary events was
17 percent (95 percent confidence interval, ¡2 to
32 percent [the negative value indicates an increase
in risk]), similar to the reduction in risk before ad-
justment. Atrial fibrillation was present at the begin-
ning of the study in 5.6 percent of the patients who
 
Figure 2.
 
 Risk Ratios for Stroke from Any Cause (Total Stroke) and Various Types of Stroke, According to Study Group.
The horizontal lines indicate 95 percent confidence intervals. The scale for risk ratios is logarithmic. Because of rounding, values
for subcategories do not necessarily sum to the category totals.
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*Because base-line data were missing for some patients, the numbers of patients do not always total 4502 in the placebo group and 4512
in the pravastatin group.
†LDL denotes low-density lipoprotein, and HDL high-density lipoprotein. To convert values for cholesterol to millimoles per liter, multiply
by 0.02586; to convert values for triglycerides to millimoles per liter, multiply by 0.01129.
‡CI denotes confidence interval. Negative values indicate an increase in risk.
§The global test for interaction (with all subgroups considered together) did not indicate a statistically significant result.
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.*
VARIABLE† PLACEBO (N=4502) PRAVASTATIN (N=4512)
REDUCTION IN RISK
WITH PRAVASTATIN
(95% CI)‡
P VALUE FOR 
HETEROGENEITY§
NO. OF 
PATIENTS
NO. OF PATIENTS
WITH STROKE (%)
NO. OF 
PATIENTS
NO. OF PATIENTS
WITH STROKE (%) %
Sex
Female
Male
760
3742
27 (3.6)
177 (4.7)
756
3756
33 (4.4)
136 (3.6)
¡26 (¡110 to 24)
25 (6 to 40)
0.09
Qualifying event
Myocardial infarction
Unstable angina
2875
1627
120 (4.2)
84 (5.2)
2879
1633
98 (3.4)
71 (4.3)
20 (¡5 to 39)
17 (¡14 to 39)
0.88
Age
<55 yr
55–64 yr
65–69 yr
»70 yr
1021
1708
1087
686
17 (1.7)
68 (4.0)
79 (7.3)
40 (5.8)
1065
1706
1081
660
17 (1.6)
48 (2.8)
58 (5.4)
46 (7.0)
4 (¡87 to 51)
31 (0 to 52)
28 (¡1 to 49)
¡21 (¡85 to 21)
0.22
Hypertension
Yes
No
1891
2609
107 (5.7)
96 (3.7)
1867 
2644
100 (5.4)
69 (2.6)
7 (¡22 to 29)
30 (4 to 49)
0.28
Diabetes
Yes
No
386
4116
40 (10.4)
164 (4.0)
396
4116
31 (7.8)
138 (3.4)
27 (¡17 to 54)
17 (¡4 to 34)
0.64
Smoking
Current
Former
None
444
2814
1244
26 (5.9)
120 (4.3)
58 (4.7)
425
2923
1164
18 (4.2)
106 (3.6)
45 (3.9)
30 (¡28 to 61)
16 (¡9 to 35)
18 (¡21 to 44)
0.88
Atrial fibrillation
Yes
No
59
4443
12 (20.3)
192 (4.3)
64
4448
9 (14.1)
160 (3.6)
31 (¡63 to 71)
18 (¡1 to 34)
0.61
Previous stroke
Yes
No
198
4303
25 (12.6)
179 (4.2)
171
4341
18 (10.5)
151 (3.5)
25 (¡39 to 60)
17 (¡3 to 33)
0.96
Transient ischemic attack
Yes
No
176
4325
13 (7.4)
191 (4.4)
156
4351
13 (8.3)
156 (3.6)
¡11 (¡139 to 49)
20 (1 to 35)
0.41
Total cholesterol
<213 mg/dl
213–250 mg/dl
»251 mg/dl
1894
2003
605
96 (5.1)
83 (4.1)
25 (4.1)
1898
2010
604
77 (4.1)
68 (3.4)
24 (4.0)
21 (¡7 to 41)
20 (¡10 to 42)
5 (¡66 to 46)
0.84
LDL cholesterol
<135 mg/dl
135–173 mg/dl
»174 mg/dl
1305
2338
859
66 (5.1)
107 (4.6)
31 (3.6)
1332
2336
844
49 (3.7)
90 (3.9)
30 (3.6)
28 (¡4 to 50)
17 (¡10 to 37)
4 (¡59 to 42)
0.61
HDL cholesterol
<39 mg/dl
»39 mg/dl
2831
1671
139 (4.9)
65 (3.9)
2890
1622
100 (3.5)
69 (4.3)
31 (10 to 46)
¡8 (¡52 to 23)
0.04
Triglycerides
<133 mg/dl
133–220 mg/dl
»221 mg/dl
2022
1801
679
92 (4.5)
72 (4.0)
40 (5.9)
1951
1750
811
83 (4.3)
55 (3.1)
31 (3.8)
8 (¡24 to 31)
22 (¡10 to 45)
37 (¡1 to 61)
0.40
Aspirin use
Yes
No
3684
611
166 (4.5)
29 (4.7)
3718
592
126 (3.4)
34 (5.7)
26 (7 to 41)
¡20 (¡97 to 27)
0.08
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had a stroke, as compared with 1.2 percent of the
patients who did not have a stroke (P<0.001). Atrial
fibrillation developed for the first time during the
study in 2.2 percent of the placebo group and 2.9
percent of the pravastatin group (P=0.06). There
was no significant difference between the pravastatin
and placebo groups in mortality after stroke (13.0
percent and 13.2 percent, respectively) or in the se-
verity of disability associated with stroke.
Relation between Base-Line Characteristics 
and the Incidence of Stroke
Table 5 shows the base-line predictors of stroke
from any cause according to the multivariate model
and the univariate model for each predictor. The risk
increased with older age and increasing systolic blood
pressure, and it was higher among patients with a
history of hypertension, diabetes, a history of stroke,
current smoking, or the presence of atrial fibrilla-
tion. The risk was higher in patients in whom unsta-
ble angina pectoris was the qualifying event than in
those with myocardial infarction as a qualifying event
and was higher in patients with previous anterior
myocardial infarction than in those with other types
of myocardial infarction. Lipid levels at base line were
not significant predictors of the occurrence of stroke
in either the total cohort or the placebo group.
Except for sex, all the predictors of overall stroke
in the multivariate analysis were also predictors of
nonhemorrhagic stroke in this analysis. Body-mass
index was also a predictor. Base-line lipid levels were
not significant predictors of the risk of nonhemor-
rhagic stroke either in the total study population or
in the placebo group. The change in the LDL cho-
lesterol level during the first year after enrollment was
not a significant predictor of overall stroke or of non-
hemorrhagic stroke in either the pravastatin group
or the total study population (P>0.1 for all compar-
isons). After adjustment for significant base-line fac-
tors, treatment with pravastatin was associated with
a reduction of 16 percent in the overall risk of stroke
(95 percent confidence interval, ¡3 to 31 percent;
P=0.10) and a reduction of 21 percent in the risk
of nonhemorrhagic stroke (95 percent confidence
interval, 3 to 36 percent; P=0.03).
DISCUSSION
This study shows that lipid-lowering therapy with
pravastatin reduces the risk of stroke in patients with
known coronary heart disease. The benefits of pra-
vastatin were achieved without adverse effects and
without an increase in the rate of hemorrhagic stroke.
Aspirin given for secondary prevention reduces the
risk of stroke by 25 percent,17 and in this study the
benefits of pravastatin were achieved in a population
in which the rate of aspirin use was high. Analysis ac-
cording to total and LDL cholesterol levels at base
line revealed no evidence of differences in the treat-
ment effect.
Previous studies reported that lowering lipid levels
with non-statin therapies as compared with placebo
or control therapy reduced the rate of coronary events
*Relative risks refer to the placebo group and were based on the hazard ratio in a time-dependent
Cox model. CI denotes confidence interval.
†Nonfatal coronary events included nonfatal myocardial infarction, unstable angina, coronary-
artery bypass grafting, and angioplasty.
TABLE 4. EVENTS DURING THE STUDY BEFORE STROKE AND THE INCIDENCE OF STROKE, 
ACCORDING TO STUDY GROUP.
CORONARY EVENTS BEFORE STROKE INCIDENCE OF STROKE
RELATIVE RISK 
(95% CI)*
PLACEBO
(N=4502)
PRAVASTATIN 
(N=4512)
no./1000 person-yr
Nonfatal myocardial infarction
No
Yes
7.6
22.5
6.2
22.4
1.0
3.1 (2.3–4.3)
Unstable angina
No
Yes
7.4
13.7
5.9
12.8
1.0
1.9 (1.5–2.4)
Coronary-artery bypass grafting
No
Yes
8.0
14.9
6.6
11.0
1.0
1.6 (1.0–2.6)
Angioplasty
No
Yes
7.8
15.7
6.4
11.6
1.0
1.8 (1.3–2.5)
Any nonfatal coronary event†
No
Yes
6.9
13.9
5.5
12.9
1.0
2.0 (1.6–2.6)
The New England Journal of Medicine 
Downloaded from nejm.org at UQ Library on April 2, 2017. For personal use only. No other uses without permission. 
 Copyright © 2000 Massachusetts Medical Society. All rights reserved. 
324 · August 3,  2000
The New England Journal  of  Medicine
but not the rate of stroke.18 The discrepancy be-
tween their results and ours could have been due to
the lower absolute rate of strokes than of coronary
events, the diverse causes of stroke, the relatively young
age of the patients in those studies (most of which
excluded patients over the age of 70 years, a sub-
group that constituted 15 percent of the population
in our study), the small overall reduction in choles-
terol levels (10 to 11 percent, as compared with ap-
proximately 18 percent in our study), and the small
number of strokes.
Post hoc analysis of the Scandinavian Simvastatin
Survival Study showed that simvastatin, as compared
with placebo, was associated with a lower incidence
of the combined end point of stroke and transient
ischemic attack (28 percent relative reduction [3.4 per-
cent vs. 4.6 percent], P=0.03) over a period of 5.4
years in patients with coronary heart disease (mean
age, 58.1 years) and with cholesterol levels of 213 to
309 mg per deciliter (5.5 to 8.0 mmol per liter).19,20
The incidence of stroke alone was nonsignificantly
lower with simvastatin (reduction in risk, 22 per-
cent; 95 percent confidence interval, ¡9 to 44 per-
cent), and the rate of aspirin use was low (37 percent
of patients at base line and 55 percent at the com-
pletion of the study). In a prespecified analysis of the
Cholesterol and Recurrent Events (CARE) Study, 132
patients had strokes, and pravastatin reduced the in-
cidence of stroke by 32 percent over a period of five
years as compared with placebo (2.6 percent vs. 3.8
percent, P<0.03) in patients who had had an infarc-
tion (mean age, 59 years) and who had average plas-
ma total cholesterol levels at base line of less than
240 mg per deciliter (6.2 mmol per liter). Eighty-
three percent of the patients in the CARE Study
were taking aspirin at base line.11,21
The results of several meta-analyses of trials of
statins, in which there were a total of 454 strokes,
have been reported.10,18,22,23 Use of statins was asso-
ciated with a significantly lower rate of stroke (24 to
32 percent lower) in secondary-prevention trials18,22
and a nonsignificantly lower rate (15 to 20 percent
lower)18,22 in primary-prevention trials.
In the LIPID study, there were 419 confirmed
strokes, and the strokes were prospectively classified
according to type. The reduction in the rate of strokes
*Because data were missing for four patients in the multivariate analysis, the numbers of patients total 9010 rather than
9014. CI denotes confidence interval, LDL low-density lipoprotein, and HDL high-density lipoprotein.
†Lipid levels (total, LDL, and HDL cholesterol) were assessed as continuous variables and were not significant risk
factors in either univariate or multivariate analysis.
‡Patients with this characteristic served as the reference group.
TABLE 5. RISK FACTORS FOR STROKE FROM ANY CAUSE.*
VARIABLE†
NO. OF 
PATIENTS UNIVARIATE ANALYSIS MULTIVARIATE ANALYSIS
RELATIVE RISK 
(95% CI) P VALUE
RELATIVE RISK 
(95% CI) P VALUE
Treatment with pravastatin 0.81 (0.66–1.00) 0.048 0.84 (0.69–1.03) 0.10
Age
<55 yr‡
55–64 yr
65–69 yr
»70 yr
2086
3411
2167
1346
1.00 
2.16 (1.47–3.17)
4.27 (2.93–6.21)
4.45 (2.99–6.62)
<0.001
1.00 
1.89 (1.28–2.78)
3.56 (2.43–5.23)
3.56 (2.37–5.37)
<0.001
Male sex 7494 1.06 (0.80–1.40) 0.69 1.34 (1.01–1.78) 0.045
Qualifying event
Anterior myocardial infarction‡
Other myocardial infarction
Unstable angina pectoris
2253
3499
3258
1.00 
0.70 (0.53–0.91)
1.05 (0.82–1.35)
0.002
1.00 
0.69 (0.53–0.91)
0.93 (0.73–1.20)
0.014
Stroke before randomization 369 3.33 (2.42–4.57) <0.001 2.25 (1.63–3.11) <0.001 
Smoking status
Never smoked‡
Former smoker
Current smoker
2408
5734
868
1.00 
0.93 (0.74–1.18)
1.23 (0.86–1.75)
0.241
1.00 
0.94 (0.74–1.20)
1.70 (1.18–2.43)
0.002
Systolic blood pressure
«125 mm Hg‡
126–140 mm Hg
>140 mm Hg
3145
3286
2579
1.00  
1.73 (1.31–2.28)
2.47 (1.88–3.25)
<0.001
1.00 
1.48 (1.12–1.95)
1.72 (1.29–2.29)
0.001
Hypertension 3758 1.79 (1.46–2.20) <0.001 1.39 (1.12–1.72) 0.003
Diabetes 782 2.69 (2.08–3.48) <0.001 2.23 (1.71–2.89) <0.001
Atrial fibrillation 123 5.00 (3.22–7.77) <0.001 3.18 (2.04–4.97) <0.001
Total cholesterol 0.94 (0.82–1.08) 0.388
LDL cholesterol 1.14 (0.73–1.76) 0.563
HDL cholesterol 0.91 (0.79–1.06) 0.245
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was consistent among the categories of ischemic
stroke, including lacunar infarcts. The number of pa-
tients with hemorrhagic stroke was small (28), and
thus no conclusions with respect to this type of stroke
can be drawn from our data.
Atheroma of the carotid arteries24 and aortic arch25
is a potent independent risk factor for stroke. The
pathophysiology of disease is less well defined in these
vascular territories than in the coronary circulation.
However, histologic lesions in the carotid arteries
similar to those that characterize unstable plaque in
the coronary circulation have been described.26
It has been reported that total and LDL choles-
terol levels may be associated with thickening of the
intima–media layer of the carotid artery, as deter-
mined by B-mode ultrasonography of the carotid ar-
tery,27,28 and indeed, lipid-lowering therapy has been
shown to reduce the progression of carotid intima–
media thickening.22,29-35 In a substudy of the LIPID
study, pravastatin reduced the development of carot-
id-wall thickening over a four-year follow-up peri-
od.35 The effect of treatment was similar among sub-
groups of patients defined according to cholesterol
level at base line.
The incidence of cardioembolic stroke in the pra-
vastatin group in our study may have been lowered
by the 29 percent reduction in the rate of myocar-
dial infarction, with its associated complications of
left ventricular mural thrombosis, heart failure, and
atrial fibrillation, that was observed with pravastatin.
The presence of atrial fibrillation at base line was a
strong predictor of overall stroke; the risk of stroke
in patients with atrial fibrillation was more than three
times that in other patients. Although new atrial fi-
brillation occurred in similar percentages of patients
in the placebo and pravastatin groups, the number
of patients in whom paroxysmal atrial fibrillation de-
veloped is not known.
Angioplasty and coronary-artery bypass surgery
were performed less frequently in the pravastatin
group than in the placebo group. The rates of stroke
associated with these procedures were similar in the
two groups. The reduction in the rate of overall
stroke cannot be explained by the reduction in the
rate of nonfatal coronary events associated with pra-
vastatin, since the estimated treatment effect was at
least as great after adjustment for these events. 
Cholesterol levels at base line were not correlated
with the risk of overall stroke or the risk of nonhem-
orrhagic stroke. There was a greater relative reduc-
tion in risk with pravastatin in patients with low
HDL cholesterol levels. This finding conflicts with
the results of the CARE Study,11 which showed a
trend in the opposite direction, and in both studies
these were probably chance findings. Similar relative
reductions in risk were seen in other subgroups de-
fined according to variables assessed at base line. The
change in LDL cholesterol from base line to one
year was also not a predictor of the likelihood of
subsequent stroke.
The benefits of pravastatin may be due to a num-
ber of mechanisms other than a lowering of lipid
levels. Statins have other effects and may reduce the
incidence of clinical events by influencing endothe-
lial function,36,37 the inflammatory response,38 plaque
stability,39 and thrombus formation.40 Our data do
not allow us to comment on the extent to which lo-
cal effects on atheroma of the carotid artery or aor-
tic arch or effects other than a reduction in the LDL
cholesterol level may have contributed to our findings.
The decrease in the risk of stroke that was associ-
ated with pravastatin was observed in patients with
previous myocardial infarction or unstable angina. It
is not known whether similar effects would be ob-
served in patients with previous stroke or transient
ischemic attack or whether stroke would be prevent-
ed in patients without manifest atherosclerosis.
The incidence of stroke is increasing as the popu-
lation ages. The costs of acute hospital care and nurs-
ing home care for patients with stroke are consider-
able.41 The most common cause of death among
patients who have had a stroke is coronary heart dis-
ease.42 Our results show that lipid-lowering therapy
with pravastatin can reduce both the rate of coro-
nary heart disease and the rate of stroke, two of the
three major public health problems in industrialized
countries, as judged by the burden of disease as meas-
ured in disability-adjusted life years.1 Recognition of
these two beneficial effects should lead to more wide-
spread use of lipid-lowering therapy. It is also possi-
ble that discussion of stroke prevention with patients
may reduce noncompliance with lipid-lowering ther-
apy, a major impediment to the clinical implementa-
tion of the results of large-scale trials such as this
one in the community.
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